Anti-angiogenic gene therapy for metastatic renal cell carcinoma produces tumor growth suppression in an athymic nude mouse model

Matthew J. Mellon, Miwon Ahn, Juan A. Jiménez, Chinghai Kao, Thomas Gardner

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose: We investigated the anti-angiogenic and antitumor properties of 2 adenoviral vectors expressing the endostatinangiostatin fusion protein Ad-EndoAngio and the soluble, endothelium specific tyrosine kinase receptor Ad-Tie2 in a mouse renal cell carcinoma xenograft model. Materials and Methods: A total of 29 bilateral subcutaneous renal cell carcinomas were induced in athymic nude mice. On days 2 and 10 following tumor establishment the mice were intratumorally injected with an adenoviral vector in the right flank only. Seven treatment groups were randomly assigned, including the control group of 7 mice, the Ad-GFP control group of 7, the Ad-Tie2 group of 9, the Ad-EndoAngio group of 8, the Ad-GFP plus Ad-Tie2 group of 7, the Ad-GFP plus Ad-EndoAngio group of 9 and the Ad-EndoAngio plus Ad-Tie2 group of 8. Tumor volume was measured biweekly for 60 days. Additionally, each treatment group was administered fluorescent rhodamine conjugated bovine serum albumin dye for vascular imaging. After establishing skin windows overlying the tumors dual photon optical imaging was used to qualitatively assess the tumor vasculature. Results: Tumors treated with Ad-EndoAngio, Ad-GFP plus Ad-EndoAngio and Ad-EndoAngio plus Ad-Tie2 demonstrated 82%, 83% and 87% growth reduction, respectively, compared to controls (p <0.001). Furthermore, in vivo imaging revealed a decrease in the number of blood vessels, lumen diameter and flow velocity in these treatment groups. Conclusions: Adenoviral vectors expressing endostatin-angiostatin fusion protein have effective anti-angiogenic action against human renal cell carcinoma cells as well as potential as a novel treatment for metastatic renal cell carcinoma.

Original languageEnglish
Pages (from-to)737-742
Number of pages6
JournalJournal of Urology
Volume179
Issue number2
DOIs
StatePublished - Feb 2008

Fingerprint

Renal Cell Carcinoma
Nude Mice
Genetic Therapy
Growth
Blood Vessels
Neoplasms
Angiostatins
Endostatins
Control Groups
Rhodamines
Optical Imaging
Receptor Protein-Tyrosine Kinases
Bovine Serum Albumin
Tumor Burden
Photons
Heterografts
Endothelium
Proteins
Coloring Agents
Skin

Keywords

  • Adenoviridae
  • Carcinoma, renal cell
  • Gene therapy
  • Kidney
  • Mice, nude

ASJC Scopus subject areas

  • Urology
  • Medicine(all)

Cite this

Anti-angiogenic gene therapy for metastatic renal cell carcinoma produces tumor growth suppression in an athymic nude mouse model. / Mellon, Matthew J.; Ahn, Miwon; Jiménez, Juan A.; Kao, Chinghai; Gardner, Thomas.

In: Journal of Urology, Vol. 179, No. 2, 02.2008, p. 737-742.

Research output: Contribution to journalArticle

@article{2cf5e050170749eb9aade6ea3880214f,
title = "Anti-angiogenic gene therapy for metastatic renal cell carcinoma produces tumor growth suppression in an athymic nude mouse model",
abstract = "Purpose: We investigated the anti-angiogenic and antitumor properties of 2 adenoviral vectors expressing the endostatinangiostatin fusion protein Ad-EndoAngio and the soluble, endothelium specific tyrosine kinase receptor Ad-Tie2 in a mouse renal cell carcinoma xenograft model. Materials and Methods: A total of 29 bilateral subcutaneous renal cell carcinomas were induced in athymic nude mice. On days 2 and 10 following tumor establishment the mice were intratumorally injected with an adenoviral vector in the right flank only. Seven treatment groups were randomly assigned, including the control group of 7 mice, the Ad-GFP control group of 7, the Ad-Tie2 group of 9, the Ad-EndoAngio group of 8, the Ad-GFP plus Ad-Tie2 group of 7, the Ad-GFP plus Ad-EndoAngio group of 9 and the Ad-EndoAngio plus Ad-Tie2 group of 8. Tumor volume was measured biweekly for 60 days. Additionally, each treatment group was administered fluorescent rhodamine conjugated bovine serum albumin dye for vascular imaging. After establishing skin windows overlying the tumors dual photon optical imaging was used to qualitatively assess the tumor vasculature. Results: Tumors treated with Ad-EndoAngio, Ad-GFP plus Ad-EndoAngio and Ad-EndoAngio plus Ad-Tie2 demonstrated 82{\%}, 83{\%} and 87{\%} growth reduction, respectively, compared to controls (p <0.001). Furthermore, in vivo imaging revealed a decrease in the number of blood vessels, lumen diameter and flow velocity in these treatment groups. Conclusions: Adenoviral vectors expressing endostatin-angiostatin fusion protein have effective anti-angiogenic action against human renal cell carcinoma cells as well as potential as a novel treatment for metastatic renal cell carcinoma.",
keywords = "Adenoviridae, Carcinoma, renal cell, Gene therapy, Kidney, Mice, nude",
author = "Mellon, {Matthew J.} and Miwon Ahn and Jim{\'e}nez, {Juan A.} and Chinghai Kao and Thomas Gardner",
year = "2008",
month = "2",
doi = "10.1016/j.juro.2007.09.017",
language = "English",
volume = "179",
pages = "737--742",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Anti-angiogenic gene therapy for metastatic renal cell carcinoma produces tumor growth suppression in an athymic nude mouse model

AU - Mellon, Matthew J.

AU - Ahn, Miwon

AU - Jiménez, Juan A.

AU - Kao, Chinghai

AU - Gardner, Thomas

PY - 2008/2

Y1 - 2008/2

N2 - Purpose: We investigated the anti-angiogenic and antitumor properties of 2 adenoviral vectors expressing the endostatinangiostatin fusion protein Ad-EndoAngio and the soluble, endothelium specific tyrosine kinase receptor Ad-Tie2 in a mouse renal cell carcinoma xenograft model. Materials and Methods: A total of 29 bilateral subcutaneous renal cell carcinomas were induced in athymic nude mice. On days 2 and 10 following tumor establishment the mice were intratumorally injected with an adenoviral vector in the right flank only. Seven treatment groups were randomly assigned, including the control group of 7 mice, the Ad-GFP control group of 7, the Ad-Tie2 group of 9, the Ad-EndoAngio group of 8, the Ad-GFP plus Ad-Tie2 group of 7, the Ad-GFP plus Ad-EndoAngio group of 9 and the Ad-EndoAngio plus Ad-Tie2 group of 8. Tumor volume was measured biweekly for 60 days. Additionally, each treatment group was administered fluorescent rhodamine conjugated bovine serum albumin dye for vascular imaging. After establishing skin windows overlying the tumors dual photon optical imaging was used to qualitatively assess the tumor vasculature. Results: Tumors treated with Ad-EndoAngio, Ad-GFP plus Ad-EndoAngio and Ad-EndoAngio plus Ad-Tie2 demonstrated 82%, 83% and 87% growth reduction, respectively, compared to controls (p <0.001). Furthermore, in vivo imaging revealed a decrease in the number of blood vessels, lumen diameter and flow velocity in these treatment groups. Conclusions: Adenoviral vectors expressing endostatin-angiostatin fusion protein have effective anti-angiogenic action against human renal cell carcinoma cells as well as potential as a novel treatment for metastatic renal cell carcinoma.

AB - Purpose: We investigated the anti-angiogenic and antitumor properties of 2 adenoviral vectors expressing the endostatinangiostatin fusion protein Ad-EndoAngio and the soluble, endothelium specific tyrosine kinase receptor Ad-Tie2 in a mouse renal cell carcinoma xenograft model. Materials and Methods: A total of 29 bilateral subcutaneous renal cell carcinomas were induced in athymic nude mice. On days 2 and 10 following tumor establishment the mice were intratumorally injected with an adenoviral vector in the right flank only. Seven treatment groups were randomly assigned, including the control group of 7 mice, the Ad-GFP control group of 7, the Ad-Tie2 group of 9, the Ad-EndoAngio group of 8, the Ad-GFP plus Ad-Tie2 group of 7, the Ad-GFP plus Ad-EndoAngio group of 9 and the Ad-EndoAngio plus Ad-Tie2 group of 8. Tumor volume was measured biweekly for 60 days. Additionally, each treatment group was administered fluorescent rhodamine conjugated bovine serum albumin dye for vascular imaging. After establishing skin windows overlying the tumors dual photon optical imaging was used to qualitatively assess the tumor vasculature. Results: Tumors treated with Ad-EndoAngio, Ad-GFP plus Ad-EndoAngio and Ad-EndoAngio plus Ad-Tie2 demonstrated 82%, 83% and 87% growth reduction, respectively, compared to controls (p <0.001). Furthermore, in vivo imaging revealed a decrease in the number of blood vessels, lumen diameter and flow velocity in these treatment groups. Conclusions: Adenoviral vectors expressing endostatin-angiostatin fusion protein have effective anti-angiogenic action against human renal cell carcinoma cells as well as potential as a novel treatment for metastatic renal cell carcinoma.

KW - Adenoviridae

KW - Carcinoma, renal cell

KW - Gene therapy

KW - Kidney

KW - Mice, nude

UR - http://www.scopus.com/inward/record.url?scp=38849147224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38849147224&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2007.09.017

DO - 10.1016/j.juro.2007.09.017

M3 - Article

VL - 179

SP - 737

EP - 742

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 2

ER -